Crystal Adam 4

What Happened Crystal Adam, President, R&D at Tango Therapeutics (TNGX), exercised 38,460 stock options on 2026-04-15 by paying $5.20 per share (total cost $199,992) and then sold those 38,460 shares in the open market at $25.00 per share for gross proceeds of $961,500. The filing also shows the corresponding derivative (the option) was disposed (reported at $0) as part of the exercise. Net cash before taxes and fees from the sequence was approximately $761,508.

Key Details

• Transaction date: 2026-04-15 (Form 4 filed 2026-04-16 — appears timely).
• Exercise: 38,460 shares acquired at $5.20 each (total $199,992).
• Sale: 38,460 shares sold at $25.00 each (gross proceeds $961,500).
• Derivative disposition: 38,460 option units reported disposed at $0 (reflects the option being exercised).
• Shares owned after transaction: not specified in the filing.
• Footnotes: Transactions were effected under a Rule 10b5-1 trading plan adopted Oct 27, 2025 (F1). The option vests over four years (25% on Feb 27, 2024, then 36 equal monthly installments) (F2).

Context

• Codes: M = exercise/conversion of a derivative (option); S = sale. This sequence is an option exercise followed by an immediate open-market sale (common for executives to realize gains).
• Because the sale was executed under a documented 10b5-1 plan, it was pre-arranged and routine rather than an ad-hoc trade.